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Abstract: Neurodegenerative diseases (NDDs) are incurable and debilitating conditions that result 
in progressive degeneration and/or death of nerve cells in the central nervous system (CNS). Iden-
tification of viable therapeutic targets and new treatments for CNS disorders and in particular, for 
NDDs is a major challenge in the field of drug discovery. These difficulties can be attributed to the 
diversity of cells involved, extreme complexity of the neural circuits, the limited capacity for tissue 
regeneration, and our incomplete understanding of the underlying pathological processes. Drug 
discovery is a complex and multidisciplinary process. The screening attrition rate in current drug 
discovery protocols mean that only one viable drug may arise from millions of screened compounds 
resulting in the need to improve discovery technologies and protocols to address the multiple 
causes of attrition. This has identified the need to screen larger libraries where the use of efficient 
high-throughput screening (HTS) becomes key in the discovery process. HTS can investigate hun-
dreds of thousands of compounds per day. However, if fewer compounds could be screened with-
out compromising the probability of success, the cost and time would be largely reduced. To that 
end, recent advances in computer-aided design, in silico libraries, and molecular docking software 
combined with the upscaling of cell-based platforms have evolved to improve screening efficiency 
with higher predictability and clinical applicability. We review, here, the increasing role of HTS in 
contemporary drug discovery processes, in particular for NDDs, and evaluate the criteria underly-
ing its successful application. We also discuss the requirement of HTS for novel NDD therapies and 
examine the major current challenges in validating new drug targets and developing new treat-
ments for NDDs. 
Keywords: high-throughput screening; HTS; neurodegenerative diseases; drug discovery; demen-
tia; brain diseases; CNS disorders; tauopathies; bioassays; dementia 
 
1. Introduction 
High-throughput screening (HTS) has increasingly been used for novel drug discov-
ery in the field of pharmaceutics replacing the traditional “trial and error” approach to 
identify therapeutic targets and validate biological effects [1–3]. HTS involves assaying 
and screening a large number of biological effectors and modulators against designated 
and exclusive targets. Thus, HTS is generally favored when little is known of the target, 
which precludes structure-based drug design, but it can also be used in parallel with other 
strategies such as computational techniques and fragment-based drug design [4,5]. HTS 
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comprises several steps including target recognition, compound management, reagent 
preparation, assay development, as well as the screening itself. Using HTS in conjunction 
with multi-well cell-based platforms allows for the identification of small molecule mod-
ulators of related biochemical and signal transduction pathways. 
Current programs for central nervous system (CNS) drug development and discov-
ery can be subdivided into four main areas: (1) Receptor and target engagement, (2) drug 
“hit” identification, (3) lead identification, and (4) drug lead optimization. Active com-
pounds resulting from HTS screens—the so-called “hits”— are the prototypes from which 
drug “leads” are ultimately formed through additional combinatorial and medicinal 
chemistry. Following the screening of several hundred thousand small-molecules, a few 
hundred “hits” may be identified, leading potentially to viable drug compounds (Figure 
1). Potential hits from the HTS must then be configured for delivery, metabolism, and 
pharmacokinetics to suggest initial lead compounds. However, these lead compounds 
generally require considerable medicinal chemistry optimization, for example, to block 
polar functional groups that may reduce high receptor affinity, in an effort to generate a 
medicine that has optimal drug metabolism and pharmacokinetic (DMPK) properties. 
Neurodegenerative diseases (NDDs) are incurable and debilitating conditions that 
result in progressive degeneration and/or death of nerve cells in the CNS [6–8]. Develop-
ing drugs for CNS disorders; in particular NDDs, has become a risky business, where 
most candidates fail after years of costly clinical and non-clinical related activities. Thus, 
one of the critical first steps in the advancement of treatments of NDDs is the development 
of accurate assays for investigating neurodegeneration [9]. While the word “neurodegen-
eration” can be applied to a wide range of characteristics that cause the loss of neuronal 
activity, neuronal death is the most direct and prominent indicator of neurodegeneration.  
The creation of successful assays includes the ability to identify the associated events 
that trigger and cause cell death. To this end, tests have been established to recognize 
biochemical events that contribute to neuronal death such as metabolic fluctuation, energy 
metabolism [10], and fragmentation of DNA [11]. Cytoprotective assays using dyes or flu-
orescent markers have been a crucial method in the past to classify therapeutics causing 
neuronal death [11–13]. Many of these tests have the benefit of being easily suited to HTS 
systems and are frequently used by pharmaceutical companies to investigate the neuro-
toxicity of drugs and their possible side effects. HTS in primary neurons combines the 
advantages of HTS with the biological importance of being able to capture critical cell 
events or homeostatic conditions that are present in disease states. Despite being difficult 
to transfect and requiring complicated culture protocols, HTS with primary neurons is 
still feasible, with increased biological and clinical relevance being worth the extra effort 
and expense [14]. For example, Sharma et al. (2013) developed a HTS method for primary 
neurons which is applicable for large-scale testing, ranging from compound libraries to 
whole-genome RNA interference (RNAi) [15]. 
Novel diagnostic technologies for temporal analysis of the neuronal region and con-
sistency of the cell membrane have been developed, providing assays to track neuro-
degeneration over time [16]. Neurons may become defective in certain NDDs long before 
they die [17]. The detection of specific disease-related impairment, especially prior to as-
sociated cell death, is therefore an important step forward in the discovery of therapeutics. 
In the case of Amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD), for ex-
ample, neurons in the nervous system’s most susceptible cell populations have been 
shown to become overactive years before noticeable clinical signs and neuropathology 
have been identified [18–20]. There are a number of abnormal characteristics and symp-
toms associated with NDDs, therefore, a major challenge remains to have a reliable screen-
ing phenotype when detecting complex disease-related signatures that can be distinct and 
predictive of disease and cell death. 
In this review, we discuss the current challenges in validating new drug targets and 
developing new treatments for NDDs. Moreover, we review the increasing role of HTS in 
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the drug discovery process focusing on existing platforms that mimic healthy and dis-
eased states of the CNS. In addition, we identify the main strengths and limitations in 
their applications towards identifying new therapeutic targets and therapeutics for NDDs. 
 
Figure 1. Steps involved in the process of drug discovery. 
Druggable targets are scanned either virtually utilizing virtual compound structure 
libraries and/or by cell-based or biochemical testing of available peptide or chemical li-
braries via high-throughput screening (HTS). Abbreviations: Food and Drug Administra-
tion (FDA). 
2. High-Throughput Screening (HTS) 
2.1. Formats and Major Considerations for HTS Platforms 
HTS involves in vitro, cell- or whole organism- based assays [21]. The most common 
readouts for biochemical assays in HTS are optical, including absorbance, fluorescence, 
luminescence, and scintillation. The efficiency of data production and cost per screen are 
the main determinants in the choice of the most suitable readout for a particular screen. 
However, the fluorescence-based techniques are considered as one of the primary detec-
tion methods [22]. This can mainly be attributed to the high sensitivity and diverse range 
of available fluorophores enabling multiplexed readouts which allow miniaturization, as-
say design stability, ease of handling, and the ability to simultaneously track several 
events in real time [23]. However, it is important to note that short wavelength excitation 
(particularly those under 400 nm) should be avoided during the development of func-
tional assays in order to reduce interference from test compounds [24–26]. This direct 
screening approach has been applied to the selection of thrombin inhibitors, HIV-protease 
inhibitors, DNA gyrase inhibitors, etc. [27–29]. Quantitative kinetics of compound binding 
can be used to gain a higher level of understanding of binding mechanisms, as it is possi-
ble to investigate the effect of structural variations in a systematic way. Association and 
dissociation rates can vary independently for a specific lead series, resulting in the rapid 
evolution of sub nanomolar-affinity leads [30]. 
Data from screens can be archived and reviewed using information management sys-
tems [31] or more laboriously, in Excel spreadsheets. The data is evaluated in order to 
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classify hits: Data points that surpass a certain specified threshold to determine a positive 
result. Importantly, the threshold limits can be quite subjective, but a value of three stand-
ard deviations from the mean signal of wells treated with DMSO, for example, is a fair 
and typical cut-off, since it offers a manageable false-positive statistical hit rate (0.15%) 
[32]. Alternatively, the maximum number of hits that can be processed may be increased 
by “cherry picking”, normally several hundred compounds can be simply picked for fur-
ther evaluation. Additionally, the median rather than the mean for a single compound can 
be used to assess hits if the screening is done in triplicate together with the use of appro-
priate statistical methods [32]. This protects against the undue influence of significant out-
lier results, which are common in these techniques.  
2.2. Main Types of HTS Assays 
2.2.1. Cell-Based Assays 
Using cell-based assays, whole pathways can be investigated generating numerous 
potential points of interest, as opposed to the analysis of particular predetermined steps 
as in biochemical assays. Moreover, cell-based assays may provide data that cannot be 
obtained from a biochemical assay, such as the existence of the pharmacological activity 
of the screened compound at a particular receptor or the intracellular target [33,34]. Con-
sequently, cell-based platforms are especially promising as important tools in the study 
of cell growth and differentiation, in examining the influence of small molecules and cell 
growth conditions on cell function and physiology, and also in understanding signaling 
pathways in mammalian cells. They have also proven to be particularly valuable in stud-
ying complex conditions such as CNS injury and NDDs, as many factors can contribute 
to a specific cellular response [35].  
HTS is frequently accomplished using scaled down cell-based methods. Cell-based 
tests enable chemical libraries to be tested for molecules that exhibit a diversity of biolog-
ical activities. In the pharmaceutical industry, cellular microarrays utilizing 96- or 384-
well microtiter plates with 2D cell monolayer cultures are commonly used [35]. Cellular 
microarrays consist of a solid framework wherein minute volumes of diverse biomole-
cules and cells can be presented, permitting the multiplexed examination of living cells 
and, subsequently, the assessment of cellular reactions [33,36]. Miscellaneous molecules 
such as antibodies, polymers and small molecules can be arrayed using automated spot-
ting technology or soft lithography [37]. Cellular microarrays are also used in small mol-
ecule screening [38,39]. The screening of small molecules in mammalian cell lines, such as 
CHO cells, could be considered as an example of utilization of such a system [40,41]. There 
is flexibility in choosing the readout when using a cell-based assay focused on a signaling 
pathway. For example, if an antibody is available, every stage in which a protein is mod-
ified (e.g., phosphorylated), translocated [42] or changed in its abundance [43–45] can be 
possible readouts [46]. Multiple NDDs have been studied both with target-based and cell-
based screens, including AD [47], PD [48], bipolar disease, autism and schizophrenia [49]. 
A key feature of cell-based screening is that multiple targets are screened at once, the 
readout being the outcome of a cellular pathway or network [50]. 
2.2.2. Biochemical Assays 
Biochemical screening utilizes a purified target protein of interest and measures the 
binding of ligands or the inhibition of enzymatic activity in vitro [51]. These assays are 
generally conducted in a competition format, in which the compound under study dis-
places a known ligand or substrate. These assays are typically conducted in 384-well 
plates, which provide a good compromise between screening volumes (20–50 µL), 
throughput, and the cost of more sophisticated screening equipment. The readout is typ-
ically an optical method such as absorbance, fluorescence or luminescence [52]. Buratti et 
al. developed a method in which the activity of a specific RNA binding protein (RBP) 
(TDP-43) was measured, and due to the established activity of this protein, RBP was 
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shown to be involved in the pathology of PD, AD, and other NDDs [53]. Additionally, 
Crowe et al. performed a novel study, screening almost 300,000 compounds to evaluate 
their effect on tau protein assembly. Formation of toxic tau oligomers in the brain is one 
of the main observed pathologic events of AD [54]. Using HTS assays based on comple-
mentary thioflavin T fluorescence and fluorescence polarization methods, the effects of 
inhibitors of tau oligomerization were determined. Specifically, that aminothieno-
pyridazines (ATPZs) caused the inhibition of fibril assembly as well as fibrillization of tau. 
Additionally, the normal ability of tau to stabilize microtubules was not affected and 
ATPZs were shown to be promising drugs to treat AD [54,55]. Scaling down of bioanalyt-
ical activities, in order to decrease production expenses, as well as simplifying transport 
and saving space in the laboratory has led to a focus on laboratory-on-a-chip technology. 
Overall, scaling down improves the efficiency of required screening [56,57]. However, this 
could be complicated by extensive time implications, error-recovery rates, and complex 
experimental design often involving an error-prone robotic operation.  
In summary, biochemical assays have the advantage that all hits found are against a 
known target by design. However, in those situations, the often costly and tedious deter-
mination of the molecular mechanisms of action would be needed, even though the target 
is known. Furthermore, due to the degree to which the predicted target was initially vali-
dated in the disease phase, the therapeutic potential of an in vitro hit can still be incon-
sistent. Even following the determination of such mechanistic details, it is difficult to pre-
dict the behavior of such compounds in a more complex cellular environment, due to var-
iability in cellular permeability and metabolism, toxicity, selectivity, and the potential off-
target activity of the compound [58]. However, cell-based assays have the benefit of de-
tecting compounds that affect a phenotype in a complex cellular environment, but still 
suffer from a poor understanding of the target and mechanism of action. In addition, these 
experiments are usually more expensive and difficult to conform to miniature HTS assays 
[9]. Figure 2 summarizes the current classification of the main HTS assays. 
 
Figure 2. General classification of high-throughput screening (HTS) assays. 
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2.3. Economics of HTS 
HTS aims to decrease the costs of drug invention [59,60]. It is necessary to address 
the economics of HTS for NDDs drug discovery especially with the escalating yearly costs 
of mental and neurological pathologies (estimated to be around USD 1 trillion [61]) in-
cluding drug sales figures (Figure 3). It is remarkable to note that 40% of these total costs 
were attributable to the lack of productivity of the affected population due to the presence 
of these diseases [62]. The financial burden of these pathologies is only likely to increase 
as they typically have long-term consequences combined with an increasingly aging pop-
ulation.  
It is crucial to extensively enhance our knowledge and understanding of CNS dis-
eases in order to be able to develop effective therapies. Interestingly, despite the number 
of individuals in the US who experience CNS disorders being more than double than peo-
ple who suffer from cardiovascular diseases (CVDs), the global market for CNS therapeu-
tics constitutes less than a third of the global drug market for CVDs [63]. Therefore, the 
CNS drug market would have to increase by over 5-fold just to correspond to the global 
market for CVDs.  
The primary explanation for this under-development of the worldwide brain drug 
market is that the vast majority of CNS drugs do not cross the in vivo blood-brain barrier 
(BBB). The BBB is a unique and highly selective vascular interface that separates the pe-
ripheral blood circulation from the neural tissue in order to maintain an optimum home-
ostatic microenvironment for brain function and protection [64,65]. However, biology’s 
proverbial double-edged sword means that the protective nature of the BBB precludes 
almost all large-molecule neurotherapeutics and more than 98% of all small-molecules as 
viable drugs [66]. In one systematic medicinal research study, over 7000 drugs were eval-
uated in the comprehensive medicinal chemistry (CMC) database [67] and this suggested 
that the CNS was affected by just 5% of these medications. In another study, only one out 
of every eight medicines analyzed were active in the CNS and only 1% of the total number 
of drugs were clinically active in the CNS for diseases [68]. 
The procedure involved in developing a new drug is an elaborative effort which is 
often a costly and lengthy process. On average, the cost of developing a new medicine is 
around USD 1.3 billion (2018) [69]. However, the expenditure of the research and devel-
opment (R&D) departments of the major pharmaceutical companies can be as high as USD 
2.87 billion (2013) to discover and test a new drug [70]. Despite these huge investments in 
new treatments targeting NNDs and an expanding pipeline, there have been more failures 
and setbacks than overall treatment successes. The failure rate of clinical trials for new 
treatments targeting NDDs, for example AD, is exceptionally high and usually exceeds 
99% [71]. For example, during the period 2010–2015, all the clinical trials of potential med-
icines for treating AD failed and were terminated after reaching phase three [72]. Recently, 
Biogen terminated both of the phase III, ENGAGE (NCT02477800), and the EMERGE 
(NCT02484547) clinical trials of Aducanumab [BIIB037], since it failed to demonstrate a 
superior activity compared to the placebo [73–75]. Consequently, Biogen lost more than 5 
years and USD 2.5 billion on the failed experimental drug Aducanumab [BIIB037] [74]. It 
is clear that R&D expenditures over time have the most impact on the overall cost of drug 
development [76]. 
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Figure 3. Total expenditure on central nervous system (CNS)-related drugs in 2010. Adapted from Gustavsson et al., 2011 
[77]. 
3. Drugs Discovery for NDDs 
3.1. Challenges in the Discovery of CNS Drugs 
CNS drugs face substantial developmental obstacles relative to non-CNS drugs, 
largely due to a limited understanding of the complex pathophysiology of many of the 
diseases they aim to treat, along with difficulties in identifying and assessing acceptable 
clinical endpoints. Approving a new drug for CNS diseases typically faces additional bur-
densome regulations. For instance, a study published by the Tufts Centre for the Study of 
Drug Development (Tufts CSDD) highlighted a real problem that hampers the discovery 
and subsequent development of CNS drugs. The study found that for the period 1995–
2007, success rates for CNS drugs were less than half of non-CNS drug approval rates 
(6.2% vs. 13.3%, respectively). Additionally, between 2000 and 2017, the time for approval, 
after submission of a marketing application for CNS drugs, was 38% longer than for non-
CNS drugs [78]. In 2017, Gribkoff and Kaczmarek analyzed the approval period and ap-
proval rates of clinical projects investigating 274 CNS and 1168 non-CNS drugs, in which 
42 CNS and 345 non-CNS compounds finally got approved by the United States Food and 
Drug Administration (USFDA) [79]. Furthermore, a new Tufts CSDD report also revealed 
that the total time required for the development process was 20% higher for CNS drugs, 
and that the number of CNS drugs given the FDA priority review was considerably lower 
compared to the non-CNS drugs [80].  
As a result, CNS drug research and development projects have been exposed to major 
layoffs and eliminations over the last decade. Although there has been recent revival of 
interest in CNS drug discovery, past shifts in the priorities of the pharmaceutical and bi-
otech industries represent the well-documented reality of CNS-drug discovery projects. 
CNS drugs in general have higher failure rates than non-CNS drugs, both preclinically 
and clinically, and in certain cases, such as for the main NDD disorders, the clinical failure 
rate for disease-modifying medications has been 100% [37]. Compared to non-CNS drugs, 
the development periods for CNS drugs are slightly longer for those drugs which are ap-
proved, and post-development regulatory approval is also longer [37,60].  
Although the last few decades have witnessed major developments in our under-
standing of basic neuroscience, such as neuropharmacology, most CNS pharmaceutical 
Bioengineering 2021, 8, 30 8 of 20 
 
treatments are distinguished not by the treatment of the cause but rather of symptoms. 
For example, most pain drugs (used in the CNS disease treatment) minimize the discom-
fort, but do not permanently influence the cause of pain. This is often acceptable for acute 
pain, especially when the cause is self-limiting, but when the drug is withdrawn chronic 
and neuropathic pain often returns. The treatment of symptoms, even if followed by se-
vere side effects, can be very effective in psychiatric conditions, but when the drug is 
stopped, the symptoms usually return without a decrease in severity [81]. The general 
degeneration (death) of neurons in AD or the more localized deaths of particular central 
cell populations in PD and ALS, contribute to increased impairment and eventual death 
in people. Currently, all of the approved treatments for these chronic NDDs are palliative 
and symptomatic therapies. 
3.2. The Need for HTS in the Discovery of Drugs for NDDs 
NDD, also known as “protein-misfolding disorders”, are a heterogeneous group of 
diseases characterized by extensive neuronal loss, cellular toxicity, and cell proteostatic 
impairment. Extensive neuropathological, biochemical, and molecular genetic studies in-
dicate that the accumulation of proteins with altered physical and chemical characteristics 
is a fundamental phenomenon in many forms of NDDs in the human brain, as well as in 
peripheral organs [82,83]. 
The precise aetiology of the majority of NDDs is highly complicated and not fully 
understood. Studies performed in the last few decades have shown that abnormal protein 
folding and deposition is a common characteristic within the different types of NDDs (see 
Figure 4). For instance, the tau protein, FUS (fused in liposarcoma)/FET protein 
(FUS/FET), TAR DNA-binding protein 43 (TDP-43), and alpha-synuclein protein (α-syn) 
can accumulate intracellularly in the nervous system. Whereas, amyloid beta protein (Aβ) 
or prion protein (PrP) are examples of proteins that can accumulate extracellularly and 
also lead to NDDs [84,85]. AD is characterized by the presence of hyperphosphorylated 
and misfolded intraneuronal aggregates of tau protein, and by the extracellular deposition 
of amyloid plaques. Lewy body (LB)-associated diseases, which include PD and Lewy 
body dementia (LBD), display intraneuronal cytoplasmic inclusions. Whereas the spo-
radic, adult-onset degenerative motion disorder of unknown aetiology, known as multi-
ple system atrophy (MSA) is characterized by a pathological aggregation of toxic forms of 
α-syn within oligodendrocytes and neurons. Deposition of neuronal tau is an important 
feature of AD, frontotemporal lobar degeneration (FTLD), primary age-related tauopathy 
(PART), neurofibrillary tangle (NFT)-dementia, and pick disease (PiD). Argyrophilic 
grain disease (AGD), progressive supra-nuclear palsy (PSP), and cortico-basal degenera-
tion (CBD) all show both neuronal and glial tau aggregates, whereas globular glial tauopa-
thies (GGT) are characterized by glial tau disorders [86,87]. Moreover, recent advances 
have demonstrated that glial cells (including astrocytes, oligodendrocytes, and microglia) 
are involved in mediating the pathophysiology of various CNS disorders including NDDs 
by activating neuroinflammation and disrupting the BBB function [88], thereby affecting 
brain water homeostasis [44] and impairing brain energy metabolism [89], all of which 
ultimately contribute to neuronal death and neurodegeneration (Figure 4). 
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Figure 4. Schematic summary of the regions of the brain affected by major neurodegenerative diseases (NDDs) and the 
misfolded proteins that are involved in their pathology. Adapted from [90,91]. 
The discovery and development of any new drug relies heavily on a detailed under-
standing of the underlying mechanisms of disease and a successful progression from the 
identification of candidates to the design of clinical trials [92]. However, our current 
knowledge and understanding of the precise aetiology of the majority of the NDDs is still 
incomplete. Even animal models recapitulate only limited aspects of each disease. The 
extent to which they can model human diseases involving complex and poorly defined 
factors is still limited and unclear due to differences in anatomy and physiology and 
hence, pathophysiological responses involved in the disease process [93–95]. This might 
partially explain the high failure of a large number of lead compounds during the in vivo 
part of clinical trials [96,97]. Lead compounds with promising safety and efficacy profiles 
can still fail during in vivo stages due to various physiochemical properties, for example, 
failing to cross the BBB due to poor lipophilicity, charge, hydrodynamic radius, and/or 
molecular weight. Therefore, it is not surprising that an extremely small number of drug 
candidates, which proceed from preclinical and animal studies to phase I clinical trials, 
have eventually made it to the bedside [98]. 
Only a small class of drugs actually cross the BBB which includes small molecules 
with high lipid solubility and a low molecular weight (Mw) of <400–500 Daltons (Da). 
However, There are a few brain diseases that reliably react to this category of small mol-
ecules, including depression, affective disorders, chronic pain, and epilepsy [67,99]. The 
classic experiment of intravenous injection of [14C]-histamine into mice has demonstrated 
the rate-limiting function of the BBB. Histamine is a small molecule of just 111 Da, but 
does not cross the BBB due to the presence of many hydrogen-bond-forming functional 
groups. In addition, BBB penetration is known to be inversely related to the number of 
hydrogen bonds (typically <8 hydrogen bonds to be able to cross BBB) [100]. Nevertheless, 
the vast majority of CNS drugs that evolved from HTS are either water soluble with a high 
degree of hydrogen bonding or have a Mw of more than 500 Da. Applying HTS to the 
discovery of CNS drugs has led to an increase in the molecular weight of drugs and a 
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decrease in the lipid solubility of drugs. Without HTS, large molecular weight medicines 
would not have been developed for the CNS due to the BBB selectivity. In fact, potential 
large-molecular weight drugs that are found to be effective in the brain may still be ne-
glected in favor of a quest for peptidomimetic small molecules [66]. Except for some en-
dogenous ligands which are already small molecules, no small molecule peptidomimetics 
have been discovered to date that are able to transport through the BBB [66]. 
It is widely accepted that toxic misfolded proteins potentially underlie many NDDs. 
However, individual targets that regulate these proteins and their detrimental down-
stream effects are still not fully understood nor established. Phenotypic screening is an 
objective approach for identifying new targets and therapeutic molecules spanning a wide 
range of models from primitive organisms such as S. cerevisiae to more pathophysiologi-
cally relevant patient-derived cellular models. 
The HTS of small molecules enables a rapid analysis of the effects of thousands or 
even millions of small molecules. Hence, it could be highly rewarding to exploit HTS in 
the field of drug discovery for NDDs. For example, AD is high on the list of leading causes 
of death in the United States and worldwide and therefore, there is a significant global 
market for disease-modifying medications for AD [101]. The number of people afflicted 
by AD is expected to increase dramatically as the “baby boom” generation ages and med-
ical advances allow more people to live longer. For instance, in 2015, it was estimated that 
there is a new case of AD every 65 seconds in the US. However, by 2050, a new case of AD 
is predicted to occur every 33 seconds, or approximately 1,000,000 new cases every year 
[101,102]. Despite the presence of a number of FDA approved drugs to treat AD, such as 
galantamine, memantine, donepezil, tacrine, and rivastigmine, these drugs provide only 
symptomatic control. Lowering the AD prevalence rate and decelerating its progression 
will require new drugs that address the underlying pathophysiology of AD at a molecular 
level [93]. Therefore, drug discovery in the arena of NDDs will hugely benefit from effi-
cient, rapid, and cost-effective approaches such as HTS to accelerate the discovery of po-
tential new drugs for the increasing cases of NDD globally. 
3.3. Modelling of NDDs for HTS 
The ethical and financial concerns, time, and labor-intensive complexity of animal 
trials together with the obstacles associated with amending these models to the require-
ments of HTS have curtailed the wide use of such models for preliminary drug screening 
assays. Furthermore, the reported failure of many clinical trials addressing NDDs has 
raised doubts on the relevance of animal disease models to humans and implied the need 
for superior research tools [71,103–106]. Nonetheless, a number of in vivo models, such as 
Zebrafish, Drosophila melanogaster, and Caenorhabditis elegans, have been successfully used 
in modelling NDDs. 
Zebrafish (Danio rerio) is a commonly used in vivo model for different NDDs 
[107,108]. Owing to their rapid development, small size, susceptibility to genetic manipu-
lation, large numbers of offspring, and transparency during development, zebrafish are a 
useful model for advanced imaging [109–111]. Therefore, it has become an increasingly 
important in vivo model (over the traditional use of mammals) for HTS and effective in 
the determination of new compound safety and efficacy [112,113]. Zebrafish, however, 
have some inherent limitations when it comes to NDD modelling. For example, their CNS 
undergoes continuous growth and life-long development of new neurons, and displays 
remarkable potential for axon and neuron regeneration following focal lesion. This poten-
tial for continued development and repair may adversely affect their potential use as a 
model for certain aspects of neurodegeneration in humans [114–116]. 
Similarly, C. elegans offer an effective in vivo model for HTS [117–119]. The major 
advantages of C. elegans are their rapid growth rate and their cost-effectiveness as a model 
for the detection of compounds that have a protective effect(s) against the harmful impacts 
of the accumulated misfolded proteins in the neurons of patients suffering from NDDs 
such as ALS [120], Huntington’s disease (HD) [121], PD [122], and AD [123,124]. Another 
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example is Drosophila melanogaster [125,126], which has similar advantages offered by 
zebrafish and C. elegans such as the rapid growth rate, amenability for genetic modifica-
tions, and successful application as a model of NDDs in HTS [127–129]. However, all of 
these models suffer from a common major drawback, the limited ability to effectively 
mimic the complex pathophysiological environment of NDDs in humans. For instance, all 
the above-mentioned models have a short lifespan which may lessen their relevancy in 
model lineage-related diseases in humans [130]. Moreover, C. elegans have a simplistic 
body plan, lack several defined tissues/organs such as blood, brain, and internal organs, 
and are evolutionarily distant from humans [131]. Moreover, Drosophila melanogaster do 
not have an adrenergic system [132]. Therefore, developing novel, and more physiologi-
cally relevant in vitro models, can bridge the gap between existing pre-clinical and human 
studies.  
Human embryonic stem cells (ESCs) and subsequently human induced pluripotent 
stem cells (iPSCs) have emerged as powerful tools due their ability to be reprogrammed 
into several distinctive tissue-specific cell types making them an ideal model for connect-
ing phenotype to genotype [133–135]. An increasing line of evidence suggests the success-
ful implementation of iPSC-based models in HTS assays for discovering drug candidates 
for NDDs [136]. The introduction of CRISPR-Cas9 technology has revolutionized genome-
editing through providing a more effective, cheaper, and faster technique than the earlier 
methods [137]. It has facilitated the generation of cell-based specific assays for various 
NDDs using genetically modified (knock-in and knockout) iPSCs [132,135,136]. Moreover, 
CRISPR-Cas9 has opened the door for developing humanized animal models of NDDs. 
Currently, humanized animal models for PD [138], AD [139], ALS [140], and HD [141] 
have been successfully generated. These models have become favored in contemporary 
studies to test promising drug candidates which have successfully passed the in vitro val-
idation [142]. 
Advanced 3D culture models using hydrogels, extracellular matrix (ECM) scaffolds, 
spheroids, organoids or organ-on-a-chip models have been developed to emulate the 
physiological environment and functionality of human organs which can be lost in tradi-
tional 2D models [143–145]. 3D culture models of the brain, BBB, or brain spinal cord bar-
rier (BSCB) have been recently validated for various NDDs [146]. These models promote 
multicellular tissue-like formation with distinctive cell–cell and cell–matrix interactions 
required for near physiological functionality [147]. Three-dimensional cell culture models 
allow for a more precise prediction of the effects of potential drugs by closely recapitulat-
ing essential facets of the brain environment, mimicking neuronal and glial cell interac-
tions, and integrating the effect of physiological blood flow, unidirectionality and access 
to oxygen and nutrients [148]. One of the major exciting steps in HTS is the development 
and implementation of the organ-on-a-chip model. The organ-on-a-chip model is a min-
iaturized microfluidic perfusion tool that enables the in vitro culture of primary cells or 
tissues for an extended duration in a format which is applicable for high throughput re-
search. These models not only preserve the cell-cell interactions and capture key structural 
and functional aspects of organs, but they also enable the use of very limited quantities of 
investigational drugs at a nano- to micro-liter scale [149]. The use of such microfluidic 
perfusion mechanisms in organ-on-a-chip models provides improved homeostatic activ-
ity through mimicking the flow of blood which not only provides nutrients, but also re-
moves catabolic metabolites and waste products [150–152]. Therefore, brain- and mi-
crovessel-on-a-chip [65,153] and human organoids [154] have recently emerged as pow-
erful tools for modelling the pathophysiology of various NDDs such as AD, PD, and HD 
since they enable a wide range of research applications, spanning the evaluation of disease 
progression, novel drug development, screening and non-invasive real-time monitoring 
of drug action [155–157]. 
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4. Current Challenges and Future Perspectives 
One of the major challenges facing the HTS in the discovery of promising “hits” for 
treating the NDDs is the limited capacity of the use of models to perfectly recapitulate the 
pathophysiological milieu of NDDs. The CNS is one of our body’s most heavily cellular-
ized tissues, and the extracellular matrix, which occupies 20% of the CNS space, is an ex-
tremely significant additional layer of complexity. Therefore, current endeavors should 
indeed be targeted at developing new models and novel screening techniques that better 
recapitulate the in vivo physiologies [158]. The brain is the most sophisticated organ in 
the human body, summarized by theoretical physicist Michio Kaku who said “the human 
brain has 100 billion neurons, each neuron connected to 10,000 other neurons. Sitting on 
your shoulders is the most complicated object in the known universe” [159]. It is this com-
plexity that means creating a model completely mimicking the physiological/pathophys-
iological conditions in the brain is not an easy nor straight forward task. However, recent 
breakthroughs in harnessing the advantages of the iPSCs in combination with the ad-
vancement in microfluidic systems and 3D culture models could lead to constructing 
brain-on-chip models that have a better ability in recapitulating pathophysiological con-
dition(s) most closely related to those in NDDs patients [160]. For instance, currently, most 
in vitro models of NDDs are comprised largely from neuronal cells, therefore, their accu-
racy, and also complexity, would be increased through adding glial cells such as astro-
cytes, microglia, pericytes, and oligodendrocytes to better mimic the molecular and struc-
tural complexity [66,161–163]. Even after drug administration, the BBB can prevent the 
passage of over 98% of small molecule drugs and other therapies to the brain [66,164]. In 
addition, the BBB impairment is known to diminish its ability to prevent the peripheral 
immune cells from infiltrating the brain, so it is implicated in exacerbating the condition 
of patients with NDDs [66] such as AD and PD [165–172]. Therefore, future 3D models for 
NDDs should incorporate the BBB to more precisely model pathophysiological conditions 
and promote the targeted delivery of therapies, whilst lowering the potential for serious 
side-effects [151,173]. 
HTS is indispensable in the field of drug discovery for NDDs. However, the capabil-
ity of HTS is not only restricted by the availability of human-relevant NDD models, but 
also limited by the quality and size of the library of the compounds screened in the HTS. 
Therefore, expanding the number of small molecules available for HTS increases the odds 
of discovering efficient disease-modifying drugs for the NDDs. Dynamic combinatorial 
chemistry (DCC) advancement, the introduction of cheminformatics to the pharmaceuti-
cal industry, along with the widespread use of artificial intelligence (AI) in the arena of 
drug discovery are expected to generate a huge number of compounds that may lead to 
more targeted drugs with activity in preliminary HTS assays [174–176]. 
Finally, in addition to the technical challenges and obstacles discussed previously, 
the elevated cost associated with the process of discovering a novel drug is one of the 
major factors that push the pharmaceutical industry away from the race to find novel 
drugs for NDDs. Interestingly, the recent advancements in exploiting AI and machine 
learning in pharmaceutics has shown enormous potential in making the process of novel 
drugs discovery cheaper and more effective [175]. Recently, a number of pharmaceutical 
companies have started to harness the power of AI through the development of algo-
rithms in the quest for drug-structure prototypes within published research papers and 
curated databases. For example, Benevolent Bio Company (New York, NY, USA) is pres-
ently exploiting AI for discovering new ways to treat ALS. Researchers at Benevolent Bio 
identified 100 potential compounds for treating ALS, but the AI intervention meant that 
only five of these potential compounds were tested in patient derived neuronal cells. Re-
searchers discovered that one of the five tested compounds had prominent activity in 
slowing the neurological symptoms of ALS in a mice model [177]. Therefore, with the aid 
of AI, the process of HTS assays for discovering a novel disease-modifying drug that tar-
gets NDDs is expected to be a less expensive and faster process in the very near future. 
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HTS informatics systems continue to embrace these new innovations and increas-
ingly help extract HTS data more efficiently from the initial assays and subsequent plat-
form analyses. In fact, researchers have also developed platforms to mimic multiorgan 
interactions that are not present in conventional tissue culture systems, using microfluid-
ics with a co-culture system with the aim of studying the pharmacokinetics of drugs [178] 
or cell-based drug metabolism [179]. Although not yet applied to the CNS, “quasi-all-
body” model systems may reveal novel key information in this field. Both fully automated 
robotic systems and dedicated workstations can be used in the automation of HTS units. 
There is an ongoing conversation around the most reliable and cost-effective automated 
HTS devices [180]. The selection between full robotic systems and assay specific work-
stations depends on multiple factors such as budget, shift patterns, and the available 
workforce. 
In conclusion, NDDs are set to become a modern “silent epidemic” placing a major 
healthcare burden on countries with aging populations. Emerging advances in HTS com-
bined with major developments in disease modelling and computational tools have be-
come fundamental in tackling this unmet clinical demand and will help towards achiev-
ing more personalized treatments and effective precision medicine in the foreseeable fu-
ture. 
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